louisakewell, Author at European Medical Journal - Page 35 of 153

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Lugano, Switzerland and San Diego, USA, 2 August, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products…

Introducing EMJ Allergy & Immunology 2.1

United Kingdom, August 03, 2017: EMJ would like to welcome you to the latest edition of EMJ Allergy and Immunology. This much-anticipated eJournal…

Review of the 61st European Academy of Allergy and Clinical Immunology Congress 2017

The largest allergy congress in the world was this year hosted in the scenic city of Helsinki, Finland.

Introducing EMJ Rheumatology 4.1

United Kingdom, August 01, 2017: A warm welcome to EMJ Rheumatology 4.1, a journal that aims to bring healthcare professionals up to date on the latest…

EULAR 2017 – Congress Highlights

Our full congress review of EULAR 2017 is out now! Find it for free in our Rheumatology 4.1 eJournal. Take a look at some of the sights from this year’s…

Neurodegeneration Biomarkers for Diagnosis of Alzheimer’s and MND

26 July, 2017 – A portfolio of CSF biomarkers corresponding to different stages of the neurodegenerative process aids diagnosis of Alzheimer’s disease…

Comprehensive Serological Diagnostics in Neurology

26 July, 2017 – Neurological disorders, including memory deficits, psychosis and seizures, can be caused by underlying autoimmune reactions.

ANTABIO Awarded Up to $8.9M from CARB-X to Accelerate the Development of Its New Treatment For Chronic Infections in Cystic Fibrosis Patients

Labège, France, 25 July, 2017 – Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs…

Orchard Therapeutics Announces That OTL-101 Has Received a Rare Paediatric Disease Designation

London, UK, 24 July, 2017 – Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative…

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

Tel-Aviv, Israel / Raleigh, NC, USA, 17 July, 2017 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”)…